Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage (QUISERMAS)

October 19, 2018 updated by: University Hospital, Tours

Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage in Prevention of Seroma Formation After Mastectomy for Breast Cancer : a Randomized Controlled Trial

The objective of this study is to compare quilting suture of the "dead space" without drainage of the pectoral area to conventional closure with drainage to prevent post-operative seroma requiring intervention (aspiration or surgical intervention) within 21 days after mastectomy for breast cancer.

Study Overview

Detailed Description

Eligible patients are patients with operable breast cancer (invasive carcinoma and/or carcinoma in situ) for whom mastectomy is recommended or preferred by the patient either alone or in association with sentinel lymph node biopsy or standard level I/II axillary node dissection

Randomization will be stratified by center and by type of surgery (mastectomy alone/ mastectomy with sentinel node biopsy / mastectomy with axillary lymph node dissection).

Two follow-up visits will be performed: at 21 days and 9 months after surgery, these appointments are conventional, thus our trial will not modify usual follow-up.

Study Type

Interventional

Enrollment (Actual)

320

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Marseille, France, 13005
        • Conception hospital
      • Marseille, France, 13009
        • Institut POALI-CALMETTES
      • Nantes, France
        • Institut de Cancérologie de l'Ouest
      • Poitiers, France
        • CHU de Poitiers
      • St Cyr sur Loire, France
        • Alliance Clinic
      • Tours, France
        • CHRU de Tours

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women ≥ 18 years and ≤ 85 years
  • Women with operable breast cancer (invasive carcinoma and/or carcinoma in situ) for whom mastectomy is recommended or preferred by the patient either alone or in association with sentinel lymph node biopsy or standard level I/II axillary node dissection
  • Women that give her informed written consent
  • French social security affiliation

Exclusion Criteria:

  • Any physical or psychiatric condition that could impair with patient's ability to cooperate with postoperative data collection.
  • Women with indication of bilateral mastectomy or immediate reconstruction.
  • Degenerative neuromuscular disease with thoracic muscular damage
  • Planned ambulatory surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Closure with conventional technique with drainage
The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.

The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.

The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent.

Other Names:
  • Conventional closure
Experimental: Quilting suture without drainage
In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.

In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.

Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.

The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area.

Other Names:
  • Quilting suture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wound seroma requiring aspiration or surgical intervention
Time Frame: Within 21 days following mastectomy

A seroma is defined as a postoperative fluid collection via palpation on clinical examination. The Common Terminology Criteria for Adverse Events (CTCAE) which is a descriptive terminology that can be used for adverse event reporting provide a grading scale for seromas (lymphoceles).

Only grade 2 and 3 seromas i.e. seromas requiring one or more aspirations or a surgical intervention will be considered as primary outcome.

Within 21 days following mastectomy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wound seroma requiring aspiration or surgical intervention
Time Frame: Within 9 months following mastectomy
Within 9 months following mastectomy
Wound seroma whatever their type (requiring or not intervention)
Time Frame: Within 21 days following mastectomy
Within 21 days following mastectomy
Wound seroma whatever their type (requiring or not intervention)
Time Frame: Within 9 months following mastectomy
Within 9 months following mastectomy
Other wound complications
Time Frame: Within 21 days following mastectomy
Within 21 days following mastectomy
Other wound complications
Time Frame: Within 9 months following mastectomy
Within 9 months following mastectomy
Surgical morbidity
Time Frame: During surgical intervention
During surgical intervention
Pain
Time Frame: Before surgery, day 1, 21 days and 9 months following mastectomy
Visual Analogue Scale
Before surgery, day 1, 21 days and 9 months following mastectomy
Homolateral shoulder movement
Time Frame: Before surgery, 21 days and 9 months following mastectomy
The range of arm movement scored from 1 to 4 according to estimated angles of arm abduction as 1 (less than 90°), 2 (90-134°), 3 (135-179°) and 4 (180°)
Before surgery, 21 days and 9 months following mastectomy
Cosmesis results
Time Frame: 21 days, 9 months following mastectomy
Cosmetic results will be documented by patient,surgeon and by an blinded adjudication committee with possible response = poor, acceptable, good and excellent
21 days, 9 months following mastectomy
Health related quality of life : EQ-5D-5L
Time Frame: Before surgery, day 1, 21 days and 9 months following mastectomy
The descriptive system comprises 5 dimensions : mobility, self care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems
Before surgery, day 1, 21 days and 9 months following mastectomy
Cost-effectiveness assessment
Time Frame: During the whole follow-up period i.e. 9 months following mastectomy
Incremental net monetary benefice
During the whole follow-up period i.e. 9 months following mastectomy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lobna OULDAMER, MD, University Hospital, Tours

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2014

Primary Completion (Actual)

October 1, 2018

Study Completion (Actual)

October 1, 2018

Study Registration Dates

First Submitted

September 29, 2014

First Submitted That Met QC Criteria

October 8, 2014

First Posted (Estimate)

October 13, 2014

Study Record Updates

Last Update Posted (Actual)

October 22, 2018

Last Update Submitted That Met QC Criteria

October 19, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • PHRCK13 - LO / QUISERMAS
  • 2014-A00901-46 (Other Identifier: ID RCB)
  • 140730B-12 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe